Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2015 Nov 9;291(1):160–170. doi: 10.1074/jbc.M115.672394

Sialic Acid on the Glycosylphosphatidylinositol Anchor Regulates PrP-mediated Cell Signaling and Prion Formation*

Clive Bate ‡,1, William Nolan , Alun Williams §
PMCID: PMC4697153  PMID: 26553874

Abstract

The prion diseases occur following the conversion of the cellular prion protein (PrPC) into disease-related isoforms (PrPSc). In this study, the role of the glycosylphosphatidylinositol (GPI) anchor attached to PrPC in prion formation was examined using a cell painting technique. PrPSc formation in two prion-infected neuronal cell lines (ScGT1 and ScN2a cells) and in scrapie-infected primary cortical neurons was increased following the introduction of PrPC. In contrast, PrPC containing a GPI anchor from which the sialic acid had been removed (desialylated PrPC) was not converted to PrPSc. Furthermore, the presence of desialylated PrPC inhibited the production of PrPSc within prion-infected cortical neurons and ScGT1 and ScN2a cells. The membrane rafts surrounding desialylated PrPC contained greater amounts of sialylated gangliosides and cholesterol than membrane rafts surrounding PrPC. Desialylated PrPC was less sensitive to cholesterol depletion than PrPC and was not released from cells by treatment with glimepiride. The presence of desialylated PrPC in neurons caused the dissociation of cytoplasmic phospholipase A2 from PrP-containing membrane rafts and reduced the activation of cytoplasmic phospholipase A2. These findings show that the sialic acid moiety of the GPI attached to PrPC modifies local membrane microenvironments that are important in PrP-mediated cell signaling and PrPSc formation. These results suggest that pharmacological modification of GPI glycosylation might constitute a novel therapeutic approach to prion diseases.

Keywords: cholesterol, glycosylphosphatidylinositol (GPI anchor), phospholipase A, prion, sialic acid

Introduction

The prion diseases are fatal neurodegenerative disorders that include scrapie in sheep and goats, bovine spongiform encephalopathy in cattle, and Creutzfeldt-Jakob disease in man. A key event in these diseases is the conversion of a normal host protein designated PrPC into disease-associated isoforms (PrPSc). In this conversion process, a portion of PrPC that is mostly α-helix and random coil becomes refolded into a β-pleated sheet in the PrPSc molecule (1). Although the presence of PrPC is essential for prion formation (2), not all cells that express PrPC are permissive for PrPSc replication. The reasons why some cells that express PrPC do not replicate PrPSc are not fully understood. Reports that the targeting of PrPC to specific membranes is required for efficient PrPSc formation (3, 4) indicate that factors that affect the cellular targeting and intracellular trafficking of PrPC are critical in determining PrPSc replication.

The majority of PrPC molecules are linked to membranes via a glycosylphosphatidylinositol (GPI)2 anchor (5). GPI anchors play a complex role in the regulation of cell membrane composition, cell signaling and protein trafficking (6). For example, the presence of a GPI anchor targets PrPC to specific membrane microdomains called rafts that are required for efficient PrPSc formation (3, 4). The role of the GPI anchor in prion diseases is controversial because transgenic mice that produce anchorless PrPC produce large amounts of soluble PrPSc (7), suggesting that the GPI anchor was not essential for PrPSc formation. In contrast, observations that neuronal cells producing anchorless PrPC were resistant to scrapie infection (8) and that monoacylated PrPC was not converted to PrPSc within neuronal cells (9) indicate that the GPI is a critical factor in facilitating membrane-associated PrPSc formation.

GPI-anchored molecules, including PrPC, are rapidly incorporated into living cells (10, 11), and introducing PrPC to prion infected cells by cell painting increased PrPSc formation (9). This technique was used to examine the role of specific GPI structures on PrPC and PrPSc formation. The GPI anchor attached to PrPC is unusual among mammalian GPIs in that it contains sialic acid (12). Neuraminidase digestion was used to produce a PrPC with a GPI anchor lacking sialic acid (desialylated PrPC), a modification that could not be achieved by genetic manipulation methods (13). We report three major observations: first, that desialylated PrPC behaves differently from PrPC with regards to its effects on membrane composition and cell signaling; second, that desialylated PrPC is not converted to PrPSc; and third, that desialylated PrPC inhibits the conversion of endogenous PrPC to PrPSc.

Experimental Procedures

Cell Lines

Prion-infected ScN2a and ScGT1 cells were grown in Ham's F-12 medium containing 2 mm glutamine and 2% fetal calf serum. To determine the effect of test preparations on PrPSc formation, ScN2a or ScGT1 cells were added to 6-well plates, allowed to adhere overnight, and then cultured in the presence or absence of test PrPC preparations. The cells were grown with daily changes of media (± PrPC preparations), and the amounts of PrPSc were evaluated after 7 days. In other experiments, ScGT1 and ScN2a cells were pretreated for 1 h with control medium or desialylated PrPC and then incubated with phospholipase A2-activating peptide (PLAP) (Bachem) for a further 1 h.

Primary Neurons

Cortical neurons were prepared from the brains of mouse embryos (day 15.5) derived from Prnp wild type(+/+) and Prnp knock-out(0/0) mice after mechanical dissociation. Neurons (106) were added to 6-well plates that had been coated with poly-l-lysine and incubated in Ham's F-12 medium containing 5% fetal calf serum for 2 h. Cultures were shaken (600 rpm for 5 min), and nonadherent cells were removed by two washes in PBS. Neurons were grown in neurobasal medium containing B27 components and 5 ng/ml nerve growth factor (Sigma) for 10 days. Immunostaining showed that the cells were greater than 95% neurofilament-positive. In some experiments, neurons were pretreated for 24 h with squalestatin (GlaxoSmithKline). The fate of PrPC preparations was determined by incubating neurons with 10 ng of PrPC or desialylated PrPC. Cells were washed to remove unbound PrPC and incubated in fresh culture medium for different time periods. For infection studies, neurons from either Prnp(0/0) or Prnp(+/+) mice were pulsed with 1 ng of PrPSc (derived from ScGT1 cells (14)) and then incubated with 10 ng of PrPC or 10 ng of desialylated PrPC. Media containing PrPC preparations were replaced daily for 10 days, and the amount of PrPSc in neurons was measured by ELISA. All experiments were performed in accordance with European regulations (European Community Council Directive, 1986, 56/609/EEC) and approved by the local authority veterinary service/ethical committee.

Cell Extracts

Treated cells were washed three times with ice-cold PBS and homogenized in an extraction buffer containing 10 mm Tris-HCl, pH 7.4, 100 mm NaCl, 10 mm EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, and 0.2% SDS at 106 cells/ml, and nuclei and large fragments were removed by centrifugation (1000 × g for 5 min). Mixed protease inhibitors (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, aprotinin, leupeptin, bestatin, pepstatin A, and E-46) (Sigma) and a phosphatase inhibitor mixture including PP1, PP2A, microcystin LR, cantharidin, and p-bromotetramisole (Sigma) were added to some membrane extracts. To determine the amount of PrPSc in cells extracts were digested with 1 μg/ml proteinase K for 1 h at 37 °C, heated to 95 °C for 5 min, and tested in a PrP ELISA as described (9).

Isolation of Detergent-resistant Membranes (DRMs)/Rafts

The cells were homogenized in an ice-cold buffer containing 1% Triton X-100, 10 mm Tris-HCl, pH 7.2, 100 mm NaCl, 10 mm EDTA, and mixed protease inhibitors (106 cells/ml), and nuclei and large fragments were removed by centrifugation (1000 × g for 5 min). The supernatant was incubated on ice for 60 min prior to further centrifugation (16,000 × g for 30 min at 4 °C). The detergent-soluble material was reserved as the normal cell membrane. The insoluble DRMs were homogenized in extraction buffer (10 mm Tris-HCl, pH 7.4, 10 mm NaCl, 10 mm EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, and 0.2% SDS and mixed protease inhibitors. After further centrifugation (10 min at 16,000 × g), the supernatant was collected as the raft fraction.

Sucrose Density Gradients

Cells were harvested with a Teflon scraper and homogenized in a buffer containing 250 mm sucrose, 10 mm Tris-HCl, pH 7.2, and 1 mm EDTA, mixed protease inhibitors, 1 mm dithiothreitol. Nuclei and cell fragments were removed by centrifugation (1000 × g for 5 min). Membranes were washed by centrifugation at 16,000 × g for 20 min at 4 °C and solubilized in an ice-cold buffer containing 1% Triton X-100, 10 mm Tris-HCl, pH 7.2, 150 mm NaCl and 10 mm EDTA. 5, 10, 15, 20, 30, and 40% sucrose solutions were prepared and layered to produce a gradient at 4 °C. Solubilized membranes were layered on top and centrifuged at 50,000 × g for 18 h at 4 °C. Serial 0.8- or 0.25-ml volumes were collected from the bottom of gradients.

Isolation of PrPC

PrPC molecules were isolated from murine GT1 neuronal cell membranes using a combination of immunoaffinity columns, size exclusion chromatography (Superdex), and reverse phase chromatography on C18 columns (Waters) as described (9). PrPC was digested with 2 units/ml endoglycosidase F (Sigma) and/or 0.2 units/ml neuraminidase (Clostridium perfringens; Sigma) for 2 h at 37 °C. TFA was added (final concentration, 0.1%), and digested PrPC was loaded onto C18 columns. The samples were eluted under a gradient of acetonitrile and water containing 0.1% TFA. 1-ml samples were collected, split into two, and lyophilized. One sample was solubilized in an extraction buffer (as above) and tested in a PrP ELISA. PrP-containing fractions were solubilized in culture medium by sonication prior to use.

Test PrPSc Preparations

PrPSc preparations consisted of supernatants collected from ScGT1 cells that were centrifuged (500 × g for 5 min) to remove cell debris and concentrated using a 10-kDa filter (Sartorius Vivaspin). Preparations were digested with 1 μg/ml proteinase K for 1 h at 37 °C to remove PrPC, and the remaining protease-resistant PrP was measured by ELISA (see below). The samples were frozen at −20 °C for storage. On the day of use, PrPSc preparations were diluted to 1 ng/ml in culture medium and sonicated before addition to cells.

PrP ELISA

Maxisorb immunoplates (Nunc) were coated with mAb ICSM18 and blocked with 5% milk powder. Samples were applied and detected with biotinylated mAb ICSM35, followed by extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate (Sigma). Absorbance was measured on a microplate reader at 405 nm, and the amount of PrP in samples was calculated by reference to serial dilutions of recombinant murine PrP (Prionics).

cPLA2 ELISA

Maxisorb immunoplates were coated with 0.5 μg/ml of mouse mAb anti-cPLA2, clone CH-7 (Upstate), and blocked. Samples were incubated for 1 h, and the amount of cPLA2 was detected using a goat polyclonal anti-cPLA2 (Santa Cruz Biotech) followed by biotinylated anti-goat IgG, extravidin-alkaline phosphatase, and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured at 405 nm, and the amount of cPLA2 protein is expressed in units: 100 units = amount of cPLA2 in extracts or immunoprecipitates from 106 untreated cells.

Activated cPLA2 ELISA

The activation of cPLA2 is accompanied by phosphorylation of the 505 serine residue, which creates a unique epitope that was measured in an ELISA using an anti-cPLA2 mAb (clone CH-7) combined with rabbit polyclonal anti-phospho-cPLA2 (Cell Signaling Technology) followed by biotinylated anti-rabbit IgG (Dako), extravidin-alkaline phosphatase, and 1 mg/ml 4-nitrophenyl phosphate). Absorbance was measured on a microplate reader at 405 nm. The results were expressed as “units activated cPLA2” with 100 units defined as the amount of activated cPLA2 in extracts derived from 106 untreated cells.

Isolation and Analysis of GPIs

GPIs were isolated and analyzed as described (13). Briefly, PrPC preparations were digested with proteinase K (100 μg/ml) overnight at 37 °C. Digested products were mixed with water-saturated butanol. The butanol phase was collected and washed with water a further three times before being loaded onto C18 columns. GPIs were eluted from C18 columns under a gradient of propanol and water. The presence of phosphatidylinositol in GPIs was determined using mAb (5AB3-11), and specific glycans were detected with biotinylated lectins. Isolated GPIs bound to nitrocellulose membranes by dot blot and were blocked with 5% milk powder. Samples were probed with mAb 5AB3-11, biotinylated Sambucus nigra lectin (detects terminal sialic acid residues bound α-2,6 or α-2,3 to galactose), biotinylated concanavalin A (detects mannose), or biotinylated Ricinus communis agglutinin I (detects terminal galactose) (Vector Laboratories). Bound lectins were visualized using extravidin peroxidase and enhanced chemiluminescence. The mAb was visualized by incubation with a horseradish peroxidase-conjugated anti-murine IgM and chemiluminescence. In other studies, GPIs were separated on silica gel 60 high performance thin layer chromatography (HPTLC) plates in a mixture of chloroform/methanol/water (10/10/3 v/v/v) and detected by mAb 5AB3-11. The concentrations of GPIs were measured by ELISA. Maxisorb immunoplates were coated with 0.5 μg/ml concanavalin A (binds mannose) and blocked with 5% milk powder in PBS-Tween. Samples were added, and any bound GPI was detected by the addition of mAb 5AB3-11 (15), followed by a biotinylated anti-mouse IgM (Sigma), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured on a microplate reader at 405 nm.

Immunoprecipitations of PrP-specific Rafts

Treated cells were homogenized in ice cold 1% Triton X-100, 10 mm Tris-HCl, pH 7.2, 100 mm NaCl, 10 mm EDTA at 106 cells/ml. Cell debris was removed from by centrifugation (1000 × g for 5 min), and the supernatant was incubated with a mAb to PrP (4F2) for 30 min at 4 °C on rollers. Magnetic microbeads containing protein G (Miltenyi Biotech) were added (10 μl/ml) for 30 min, and protein G-bound antibody complexes were isolated using a μMACS magnetic system (Miltenyi Biotech) at 4 °C. The amounts of sialylated gangliosides in precipitates were determined by diluting precipitates from 106 cells in 1 ml of carbonate buffer and plating in Maxisorb immunoplates overnight. The plates were blocked with 5% milk powder in PBS-Tween, and sialylated gangliosides were detected by the addition of biotinylated S. nigra lectin followed by extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured on a microplate reader at 405 nm. Gangliosides within immunoprecipitates were separated by HPTLC in a solvent containing chloroform/methanol/water (6/4/1 v/v/v). Plates were blocked, and sialic acid containing gangliosides were detected by incubation with biotinylated S. nigra lectin, extravidin-peroxidase, and chemiluminesence.

Western Blot

Samples were dissolved in 50 μl of Laemmli buffer, boiled, and subjected to electrophoresis on a 15% polyacrylamide gel. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biosciences) by semidry blotting. Membranes were blocked using 10% milk powder in PBS containing 0.2% Tween 20. PrP was detected by incubation with mAb ICSM18, β-actin by mAb AC-74 (Sigma), and cPLA2 with mAb CH-7, followed by a secondary anti-mouse IgG conjugated to peroxidase. Bound antibody was visualized by chemiluminescence.

Cholesterol and Protein Content

Cholesterol and protein content were determined in cell membrane extracts. Protein concentrations were measured using a micro-BCA protein assay kit (Pierce). The concentrations of cholesterol were measured using the Amplex Red cholesterol assay kit (Invitrogen). Cholesterol is oxidized by cholesterol oxidase to yield hydrogen peroxide, which reacts with 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin. Fluorescence was measured by excitation at 550 nm and emission detection at 590 nm. The concentration of cholesterol was calculated by reference to cholesterol standards.

Statistical Analysis

Comparison of treatment effects was carried out using Student's paired t-tests, one-way and two-way analysis of variance with Bonferroni's post hoc tests (IBM SPSS statistics 20). Error values are S.D., and significance was determined, where p < 0.01. Correlations between data sets were analyzed using Pearson's bivariate coefficient (IBM SPSS statistics 20).

Results

Deglycosylated PrPC Is Converted to PrPSc

Initial studies were performed to determine whether the N-linked glycans that are attached to PrPC affect PrPSc formation in ScGT1 cells. N-Linked glycans were removed from PrPC by digestion with endoglycosidase F (16) (Fig. 1A), and deglycosylated PrPC was isolated on C18 columns (Fig. 1B). The addition of PrPC or endoglycosidase F-digested PrPC (deglycosylated PrPC) increased the PrPSc content of ScGT1 cells in a dose-dependent manner (Fig. 1C); there were no significant differences in the amounts of PrPSc in cells incubated with PrPC or with deglycosylated PrPC. Similarly, the addition of 10 ng deglycosylated PrPC increased the amount of PrPSc in ScN2a cells (4.7 ng PrPSc/106 cells ± 1.1 compared with 1.5 ng PrPSc ± 0.7, n = 15, p < 0.05). Because the absence of N-linked glycans did not significantly affect PrPSc formation in these cells, all the following experiments were performed with deglycosylated PrPC preparations.

FIGURE 1.

FIGURE 1.

N-Linked glycans did not affect the conversion of PrPC to PrPSc. A, immunoblot showing PrPC (lane 1) and deglycosylated PrPC (lane 2) separated by PAGE. B, the amounts of deglycosylated PrPC (●) in fractions from C18 columns eluted under a gradient of propanol and water. C, the amounts of PrPSc in ScGT1 cells treated daily with concentrations of PrPC (□) or deglycosylated PrPC (■) as shown for 7 days. The values are means ± S.D. from triplicate experiments performed four times (n = 12).

Sialic Acid on the GPI Anchor of PrPC Is Necessary for PrPSc Formation

The GPI anchor attached to PrPC is unusual for mammalian GPIs in that it contains sialic acid as first described by Stahl et al. (12) and illustrated in Fig. 2A. To confirm the presence of sialic acid in our PrPC preparations, GPIs were isolated from PrPC and desialylated PrPC (neuraminidase-digested) by reverse phase chromatography (Fig. 2B). GPIs derived from PrPC and desialylated PrPC eluted at different concentrations of propanol. HPTLC analysis confirmed that neuraminidase digestion altered the migration of the GPI isolated from PrPC consistent with the loss of sialic acid (Fig. 2C). Isolated GPIs were blotted onto nitrocellulose membranes and probed with mAb 5AB3-11 and biotinylated lectins. The digestion of PrPC with neuraminidase did not affect the binding of mAb 5AB3-11 (binds to phosphatidylinositol) or concanavalin A (binds to mannose) to the GPIs, showing that similar amounts of GPIs were added to blots. S. nigra lectin (which reacts with terminal sialic acid bound either α-2,6 or α-2,3 to galactose) bound to GPIs isolated from PrPC, but not to GPIs derived from neuraminidase-digested PrPC, indicating that sialic acid had been removed (Fig. 2D). The lectin R. communis agglutinin I bound to neuraminidase-digested GPIs, indicating that terminal galactose had been exposed.

FIGURE 2.

FIGURE 2.

Neuraminidase removed the sialic acid from the GPI anchor attached to PrPC. A, cartoon showing the putative structures of the GPI anchor attached to PrPC and the desialylated PrPC. Glycan residues shown include mannose (Man), sialic acid (SA), galactose (Gal), inositol (Inos), N-acetyl galactosamine (GalNAc), and glucosamine (GlcN). B, GPIs isolated from PrPC (○) and desialylated PrPC (●) were separated by reverse phase chromatography using a C18 column. GPIs were detected with mAb 5AB3-11 reactive with phosphatidylinositol. C, HPTLC showing the migration of GPIs derived from PrPC (lane 1) or desialylated PrPC (lane 2) separated on silica 60 plates. D, dot blots showing the binding of mAb 5AB3-11 (phosphatidylinositol), biotinylated concanavalin A (mannose), biotinylated S. nigra lectin (sialic acid), and biotinylated R. communis agglutinin I (galactose) to GPI anchors isolated from PrPC or desialylated PrPC.

The observation that PrPSc does not replicate in Prnp(0/0) neurons (14) allowed us to examine whether desialylated PrPC was converted to PrPSc. Both PrPC and desialylated PrPC bound readily to recipient Prnp(0/0) neurons; following the addition of 10-ng PrPC preparations for 2 h, there was no significant difference in the amounts of PrPC and desialylated PrPC bound (9.4 ng of PrPC ± 0.9 compared with 9.7 ng ± 0.9, n = 9, p = 0.7). Neurons from Prnp(0/0) mice were pulsed with 1 ng of PrPSc for 2 h and incubated with culture media containing control medium, 10 ng of PrPC, or 10 ng of desialylated PrPC. Media containing the PrPC/desialylated PrPC was replaced daily for 10 days when the amounts of PrPSc in neurons were measured. We did not detect any PrPSc in neurons that had been pulsed with 1 ng of PrPSc and incubated with control medium, suggesting that original inoculum was degraded by these neurons. However, PrPSc pulsed neurons incubated daily with 10 ng PrPC contained 25.7 ng of PrPSc ± 4.2, n = 12, indicating that some of the added PrPC was converted to PrPSc. In contrast, no PrPSc was detected in neurons pulsed with 1 ng of PrPSc and incubated daily with 10 ng of desialylated PrPC, indicating that it was not converted to PrPSc (Fig. 3A). Immunoblots confirmed the ELISA data and showed that PrPSc was formed in Prnp(0/0) neurons pulsed with PrPSc and incubated daily with PrPC but not in neurons pulsed with PrPSc and incubated daily with control medium or with desialylated PrPC (Fig. 3B).

FIGURE 3.

FIGURE 3.

Desialylated PrPC is not converted to PrPSc. A, the amounts of PrPSc in Prnp(0/0) neurons pulsed with 1 ng of PrPSc and incubated daily with control medium, 10 ng of PrPC, or 10 ng of desialylated PrPC for 10 days. The values are means ± S.D. from triplicate experiments performed four times (n = 12). B, immunoblots showing the amounts of β-actin and PrPSc in extracts of Prnp(0/0) neurons pulsed with 1 ng of PrPSc and incubated daily with control medium (lane i), 10 ng of PrPC (lane ii), or 10 ng of desialylated PrPC (lane iii) for 10 days.

Desialylated PrPC Reduced PrPSc Formation

Next, the effects of desialylated PrPC on the conversion of endogenous PrPC to PrPSc were determined. For this study, neurons derived from Prnp(+/+) mice were pulsed with 1 ng of PrPSc for 2 h and incubated for a further 10 days with 10 ng of PrPC or 10 ng of desialylated PrPC. Neurons pulsed with PrPSc and incubated in control medium contained 40.2 ng of PrPSc ± 5.2, n = 12. The addition of PrPC increased the amount of PrPSc in neurons to 68.5 ng of PrPSc ± 7.1, n = 12, whereas the addition of desialylated PrPC reduced the amount of PrPSc to 5.2 ng/ml (Fig. 4, A and B), indicating that desialylated PrPC suppressed the conversion of PrPC to PrPSc. Furthermore, when neurons from Prnp(0/0) mice were pulsed with 1 ng of PrPSc and incubated with 10 ng of PrPC or a mixture of 10 ng of PrPC and 10 ng of desialylated PrPC for 10 days the presence of desialylated PrPC reduced PrPSc production (Fig. 4C). Similarly, the daily addition of desialylated PrPC reduced the PrPSc content of recipient ScN2a cells (Fig. 4D) and ScGT1 cells (Fig. 4E).

FIGURE 4.

FIGURE 4.

Desialylated PrPC inhibited PrPSc formation. A, the amounts of PrPSc in Prnp(+/+) neurons pulsed with 1 ng of PrPSc and incubated daily with control medium (□), 10 ng of PrPC or 10 ng of desialylated PrPC (■) for 10 days. The values means ± S.D. from triplicate experiments performed four times (n = 12). B, immunoblots showing amounts of β-actin and protease-resistant PrP in neurons pulsed with 1 ng of PrPSc and incubated daily with control medium (lane 1), 10 ng of PrPC (lane 2), or 10 ng of desialylated PrPC (lane 3) for 10 days. C, the amounts of PrPSc in Prnp(0/0) neurons pulsed with 1 ng of PrPSc and incubated daily with control medium, 10 ng of PrPC, or a combination of 10 ng of PrPC and 10 ng of desialylated PrPC for 10 days. The values are means ± S.D. from triplicate experiments performed four times (n = 12). D, the amounts of PrPSc in ScN2a cells treated daily with control medium (□) or desialylated PrPC (■) as shown for 7 days. The values are means ± S.D. from triplicate experiments performed four times (n = 12). E, the amounts of PrPSc in ScGT1 cells treated daily with control medium (□) or desialylated PrPC (■) as shown for 7 days. The values are means ± S.D. from triplicate experiments performed four times (n = 12).

Sialic Acid on the GPI Anchor Affects the Fate of PrPC

To determine the mechanism(s) involved in desialylated PrPC-induced suppression of PrPSc formation, its properties in noninfected cells were examined. Both PrPC and desialylated PrPC bound readily to recipient Prnp(0/0) neurons. The targeting of PrPC to DRMs is necessary for efficient prion formation (4), and following the addition of 10-ng PrPC preparations, similar amounts of PrPC and desialylated PrPC were found within DRMs (8.2 ng of PrPC ± 0.9 compared with 8.1 ng of desialylated PrPC ± 1.2, n = 9, p = 0.7). PrPC and desialylated PrPC were found within different membrane rafts; after Prnp(0/0) neurons pulsed with 10 ng of PrPC or 10 ng of desialylated PrPC were homogenized in ice-cold Triton X-100 (which maintains the integrity of membrane rafts) and subjected to sucrose density gradient analysis; the desialylated PrPC was found in lower density rafts than those containing PrPC (Fig. 5A). These rafts were examined in detail after immunoprecipitation. Similar amounts of PrPC and desialylated PrPC were obtained in each precipitate (Fig. 5B). However, the rafts isolated with PrPC contained significantly less cholesterol than rafts surrounding desialylated PrPC (Fig. 5C). HPTLC analysis of immunoprecipitates demonstrated that rafts containing desialylated PrPC contained more sialylated gangliosides than did membranes surrounding PrPC (Fig. 5D). ELISA studies confirmed that rafts co-precipitated with desialylated PrPC contained significantly more sialylated gangliosides than rafts co-precipitated with PrPC (Fig. 5E).

FIGURE 5.

FIGURE 5.

Sialic acid on the GPI affects the composition of membrane rafts. Prnp(0/0) neurons were pulsed with 25 ng of PrPC or 25 ng of desialylated PrPC and homogenized in ice-cold Triton X-100. A, the amounts of PrPC (□) and desialylated PrPC (■) in membranes separated on a sucrose density gradient. The values are means ± S.D. from an experiment run in triplicate. Membrane rafts containing PrPC were isolated by precipitation with the PrPC-reactive mAb 4F2. B, blots showing the amounts of PrPC and desialylated PrPC in immunoprecipitates. C, the concentrations of cholesterol in precipitates from PrPC (□) or desialylated PrPC (■). The values are means ± S.D. from four precipitates, each measured in triplicate (n = 12). *, cholesterol significantly higher than in PrPC precipitates (p < 0.05). D, gangliosides in immunoprecipitates from cells incubated with PrPC (lane 1) or desialylated PrPC (lane 2) separated by HPTLC on silica 60 plates. E, the concentrations of gangliosides in precipitates of PrPC (□) or desialylated PrPC (■). The values are means ± S.D. from four precipitates, each measured in triplicate (n = 12). *, gangliosides significantly higher than in PrPC precipitates (p < 0.05).

Reducing cellular cholesterol concentrations destabilized some rafts, resulting in the relocation of PrPC from rafts to detergent-soluble materials (4). Here we examined whether the targeting of desialylated PrPC to DRMs was also sensitive to cholesterol depletion. Prnp(0/0) neurons pretreated with the cholesterol synthesis inhibitor squalestatin for 24 h were pulsed with 10 ng of PrPC or 10 ng of desialylated PrPC and DRMs (rafts) isolated. Whereas squalestatin reduced the amounts of PrPC in rafts, desialylated PrPC remained within rafts (Fig. 6A). The concentrations of cholesterol within cell membranes were reduced by squalestatin in a dose-dependent manner. There was a significant correlation between amounts of raft PrPC, but not desialylated PrPC, and concentrations of cholesterol in squalestatin-treated cells (Fig. 6B). Neurons incubated with PrPC/desialylated PrPC were also treated with PI-PLC for 1 h. Although digestion with PI-PLC reduced the amounts of cell-associated desialylated PrPC to less than 0.5 ng (indicating that all desialylated PrPC was expressed at the cell surface), 3.6 ng of PrPC ± 0.4 remained cell-associated after PI-PLC digestion (Fig. 6C). Increasing the concentration of PI-PLC, or incubation period, did not affect the amounts of cell-associated PrPC, suggesting that there is a pool of PrPC that is not expressed at the surface of neurons. Because proteins with different GPI anchors traffic via different pathways (17, 18), the effect of the GPI anchor on the fate of PrPC within cells was investigated. Prnp(0/0) neurons were pulsed with 10 ng of PrPC preparations, and the amounts of PrPC were measured at time points thereafter. Whereas PrPC was rapidly cleared from neurons and was absent after 48 h, desialylated PrPC remained in neurons for up to 96 h (Fig. 6D). Some GPI-anchored proteins are released from cells following the glimepiride-induced activation of an endogenous GPI-PLC (19, 20). Treatment with 5 μm glimepiride caused the release of PrPC but not desialylated PrPC (Fig. 6E).

FIGURE 6.

FIGURE 6.

Sialic acid on the GPI anchor affects the stability of PrPC. A, the amounts of PrPC in rafts (DRMs) from Prnp(0/0) neurons pretreated with squalestatin as shown and pulsed with 10 ng of PrPC (□) or desialylated PrPC (■) for 2 h. The values are means ± S.D. from triplicate experiments performed four times (n = 12). *, significantly less PrPC in rafts. B, there was a significant correlation between concentrations of cholesterol and concentrations of PrPC (○), but not desialylated PrPC (●), in rafts derived from Prnp(0/0) neurons pretreated with squalestatin and pulsed with 10 ng of PrPC/desialylated PrPC for 2 h, Pearson's coefficient = 0.41, p < 0.01. C, the amounts of PrPC in Prnp(0/0) neurons pulsed with 10 ng of PrPC (□) or desialylated PrPC (■) for 2 h and incubated with control medium or PI-PLC for 1 h. The values are means ± S.D. from triplicate experiments performed three times (n = 9). *, significantly less desialylated PrPC after digestion with PI-PLC. D, the amounts of PrPC remaining Prnp(0/0) neurons pulsed with 10 ng of PrPC (□) or desialylated PrPC (■) measured at time points thereafter. The values are means ± S.D. from triplicate experiments performed three times (n = 9). *, significantly more desialylated PrPC remaining in neurons. E, the amounts of PrPC in Prnp(0/0) neurons incubated for 2 h with 10 ng of PrPC (□) or 10 ng of desialylated PrPC (■) and treated with control medium or 5 μm glimepiride for 1 h. The values are means ± S.D. from triplicate experiments performed three times (n = 9). *, significantly less PrPC in neurons after treatment with glimepiride.

Desialylated PrPC Reduced the Activation of cPLA2 in Prion-infected Cells

Because the concentration of cholesterol within cell membranes affects PrPSc formation (4), the effects of PrPC and desialylated PrPC on cholesterol in prion-infected cells were also examined. The amount of cholesterol in ScGT1 cell membranes was significantly increased after incubation with 10 ng of PrPC (744 ng of cholesterol/106 cells ± 84 compared with 534 ± 48, n = 9, p < 0.05) or with 10 ng of desialylated PrPC (771 ng of cholesterol/106 cells ± 76 compared with 534 ± 48, n = 9, p < 0.05). Critically there was no significant difference in the amounts of cholesterol between ScGT1 cells treated with PrPC or with desialylated PrPC (744 ng of cholesterol/106 cells ± 84 compared with 771 ± 76, n = 9, p < 0.36).

Because PrPSc formation is dependent upon the activation of cPLA2 (21), the effects of desialylated GPI on this enzyme were studied. The addition of 25 ng of desialylated PrPC significantly reduced the amounts of activated cPLA2 in both ScN2a and ScGT1 cells (Table 1). However, desialylated PrPC did not affect PLAP-induced activation of cPLA2, showing that it did not have a direct effect upon cPLA2. The possibility that the addition of PLAP could restore PrPSc formation in cells treated with desialylated PrPC was investigated. PrPSc was not detected in ScGT-1 cells treated with a combination of 25 ng of desialylated PrPC and 1 μm PLAP (PrPSc<0.05 ng/106 cells), showing that nonselective activation of cPLA2 was not sufficient to reverse desialylated PrPC-induced suppression of PrPSc formation.

TABLE 1.

Sialic acid in the GPI anchor affected prion-mediated activation of cPLA2

The amounts of activated cPLA2 in cell extracts from ScN2a or ScGT1 cells pretreated with control medium or with 25 ng of desialylated PrPC and then incubated with 1 μm PLAP for 1 h. The values are the means ± S.D. from triplicate experiments performed five times (n = 15). The amount of activated cPLA2 in untreated cells was standardized as 1 for each cell line.

Treatment Activated cPLA2
ScN2a cells ScGT1 cells
units/106 cells
None 1.0 ± 0.14 1.0 ± 0.11
Desialylated PrPC 0.48 ± 0.12 0.6 ± 0.18
PLAP 3.87 ± 0.58 2.42 ± 0.28
Desialylated PrPC + PLAP 3.52 ± 0.49 2.22 ± 0.29

The clustering of GPIs in the membrane that arises as a consequence of the self-aggregation of PrPSc molecules can be mimicked by mAb-mediated cross-linkage of PrPC, which also activates cPLA2 (22). When Prnp(0/0) neurons were pulsed with PrPC or desialylated PrPC and incubated with mAb 4F2 cross-linkage of PrPC, but not desialylated PrPC, it caused a dose-dependent increase in activated cPLA2 (Fig. 7A). Furthermore, when Prnp(+/+) neurons were pulsed with desialylated PrPC and incubated with mAb 4F2 to cross-link PrPC, the presence of desialylated PrPC reduced activated cPLA2 in a dose-dependent manner (Fig. 7B).

FIGURE 7.

FIGURE 7.

Desialylated PrPC reduces activation of cPLA2 by cross-linkage of PrPC. A, the amounts of activated cPLA2 in Prnp(0/0) neurons pretreated with PrPC (□) or desialylated PrPC (■) as shown and incubated with mAb 4F2. The values are means ± S.D. from triplicate experiments performed three times (n = 9). B, the amounts of activated cPLA2 in Prnp(+/+) neurons pretreated with desialylated PrPC as shown and incubated with mAb 4F2. The values are means ± S.D. from triplicate experiments performed three times (n = 9).

Sialic Acid on the GPI Anchor Stabilized cPLA2 within PrP-containing Rafts

Upon activation, cPLA2 migrates from the cytoplasm to rafts (9, 23). Sucrose density gradients showed that in untreated ScGT1 cells, most of the cPLA2 was in low density membranes (fractions 9–12), whereas in cells that had been incubated with 25 ng of desialylated PrPC, a proportion of cPLA2 had relocated to fractions 4–7 (Fig. 8A). Immunoprecipitation studies showed that cPLA2 was found within PrPSc-containing rafts (9), raising the possibility that the sialic acid moiety on the GPI attached to PrPC or PrPSc is required to capture cPLA2 within lipid rafts. This hypothesis was tested by treating Prnp(+/+) neurons with 10 ng of PrPC or 10 ng of desialylated PrPC followed by the cross-linkage of PrPC by mAb 4F2. Although precipitates contained similar amounts of PrPC, the precipitates from neurons incubated with PrPC contained more cPLA2 than precipitates from neurons containing desialylated PrPC (Fig. 8B).

FIGURE 8.

FIGURE 8.

Desialylated PrPC reduced the targeting of cPLA2 to rafts. A, the amounts of cPLA2 in membrane extracts separated on a sucrose density gradient from ScGT1 cells treated with control medium (□) or 25 ng of desialylated PrPC (■). The values are means ± S.D. from an experiment run in triplicate. B, immunoblots showing amounts of PrPC and cPLA2 precipitated by mAb 4F2 (reactive with PrPC) from wild type Prnp(+/+) neurons treated for 3 h with control medium or 25 ng of desialylated PrPC.

Discussion

Recent studies suggest that differential glycosylation of the GPI anchor can affect the properties of some proteins, including protein structure (24), membrane localization, and intracellular trafficking (25). Here we show that sialic acid in the GPI affected the composition of the membranes surrounding PrPC, cell signaling, and the conversion of PrPC to PrPSc.

Desialylated PrPC was created by the sequential digestion of PrPC with a endoglycosidase F (to remove N-linked glycans) followed by neuraminidase to remove sialic acid. The removal of N-linked glycans was necessary to show that the effects of the subsequent neuraminidase digestion was upon sialic acid contained within the GPI anchor and not due to the removal of sialic acid contained within the N-linked glycans. Prnp(0/0) neurons exposed to PrPSc demonstrated that although PrPC was converted to PrPSc, desialylated PrPC was not. Consequently, the factors that prevented the conversion of desialylated PrPC to PrPSc were examined. Both PrPC and desialylated PrPC bound to recipient cells, increased the concentrations of cholesterol in cell membranes, and were targeted to rafts. However, membrane rafts are heterogeneous (26), and the composition of the GPI anchor is thought to target proteins to specific rafts. For example, PrPC and Thy-1 have different GPI anchors and are targeted to different rafts (27), and replacing the GPI of PrPC with that of Thy-1 altered the trafficking of PrPC to apical membranes (28). Therefore, it is possible that the differences in their GPIs direct PrPC and desialylated PrPC to different rafts and consequently their trafficking within cells.

GPI-anchored proteins are surrounded by specific phospholipids, glycolipids, and cholesterol that constitute a raft, the composition of which is dependent upon multiple interactions between the protein, glycans, and membrane lipids (29). Thus, a change in the composition of the GPI anchor attached to a protein could affect the composition of the surrounding raft. This hypothesis is supported by observations that the composition of GPIs attached to Thy-1 differs from those attached to PrPC (12, 30), and the membranes surrounding these molecules have different lipid compositions (31). We hypothesize that the presence of sialic acid in the GPI has a direct effect upon the composition of the surrounding membrane rafts as illustrated in Fig. 9 (A and B). Our observation that the rafts surrounding desialylated PrPC contained more cholesterol and sialylated gangliosides than those surrounding PrPC supported this hypothesis. In addition, treatment with glimepiride caused the release of PrPC, but not desialylated PrPC, suggesting that only PrPC is associated with a raft containing endogenous GPI-PLC. How sialic acid affects the composition of rafts is unknown. One possibility is that the sialic acid contained within the GPI competes with gangliosides for sialic acid-binding proteins within rafts. Thus, the removal of sialic acid from the GPI would allow the incorporation of gangliosides, which are associated with the suppression of PrPSc formation (32), into rafts. Gangliosides help sequester cholesterol and stabilize rafts (33, 34) especially in brain tissue (35). The increased amounts of gangliosides that surround desialylated PrPC would be expected to form a raft containing more cholesterol, as was demonstrated in these experiments. The concentrations of cholesterol in cell membranes affects membrane rigidity and helps stabilize membrane rafts (36). We noted that desialylated PrPC remained within rafts in cholesterol-depleted cells, whereas PrPC was relocated to detergent-soluble materials, a finding indicating that the rafts surrounding desialylated PrPC are more cholesterol-dense and hence more resistant to cholesterol depletion than those surrounding PrPC. Such observations are compatible with reports that the amount of gangliosides in rafts affects the expression and function of some GPI-anchored proteins (37, 38) including PrPC (39).

FIGURE 9.

FIGURE 9.

PrPC with sialic acid may alter the underlying cell membrane. A and B, schematic showing the proposed membranes surrounding PrPC (A) and desialylated PrPC (B) that include cholesterol, saturated phospholipids, unsaturated phospholipids, and gangliosides. C, proposed interactions between PrPC and PrPSc and its effects on the surrounding membrane including the incorporation of cPLA2 into membranes. D, proposed interactions between desialylated PrPC and PrPSc and its effects on the surrounding membrane including gangliosides.

Our observation that desialylated PrPC remained in cells longer than PrPC suggests that sialic acid in the GPI anchor affects the trafficking of PrPC. The endocytosis of PrPC involves a step in which it moves out of rafts and enters clathrin-coated pits (17, 40). We speculate that desialylated PrPC stabilized within cholesterol-dense rafts does not to move out of rafts nor undergo the same endocytic process as PrPC. It is possible that the cellular location of desialylated PrPC results in reduced interactions with PrPSc, which would explain why desialylated PrPC was not converted to PrPSc.

Desialylated PrPC also inhibited the conversion of endogenous PrPC to PrPSc in primary cortical neurons and ScN2a and ScGT1 cells. Previously we had shown that monoacylated PrPC reduced prion formation (9), and others have demonstrated that co-expression of mutant prion proteins alters the cellular localization of wild type PrPC and portioning into DRMs/rafts (41). One possibility is that desialylated PrPC competes with endogenous PrPC for specific partner proteins involved in endocytosis and that the depletion of these partner proteins alters the trafficking of endogenous PrPC and hence PrPSc formation. Here we explored the concept that the binding of desialylated PrPC to PrPSc modifies the rafts that are involved in PrPSc formation (3). The composition and hence the function of rafts is dynamic and controlled by an “induced fit” model (26). Because the composition of membranes is affected by the glycan structure of GPIs (29, 31), the membrane surrounding a complex between PrPSc and PrPC (Fig. 9C) would be expected to differ from membranes surrounding PrPSc and desialylated PrPC (Fig. 9D). Studies in T and B cell receptor signaling show that the coalescence of raft outer membrane proteins affects the composition of the cytoplasmic leaflet and its association with signaling molecules (4245). We propose that the binding of desialylated PrPC to PrPSc changes the composition of the local membrane so that it is unfavorable for the conversion of PrPC to PrPSc.

The hypothesis that the clustering of sialic acid-containing GPIs attached to PrP leads to the activation of cPLA2, a factor that promotes PrPSc formation (21), was explored. This occurs naturally as a consequence of PrPSc self-aggregation and experimentally following cross-linkage of PrPC by mAbs. Whereas cross-linkage of PrPC activated cPLA2, cross-linkage of desialylated PrPC had no affect, demonstrating that sialic acid was required (13). Cross-linkage of a mixture of PrPC and desialylated PrPC reduced activation of cPLA2 when compared with cross-linkage of PrPC alone (13), indicating that homogeneity of the GPI anchors was critical. Notably the presence of desialylated PrPC did not affect the activation of cPLA2 by PLAP, indicating that it did not have a direct effect upon this enzyme.

To understand how desialylated PrPC inhibited activation of cPLA2, the cellular location of cPLA2 was examined. The activation of cPLA2 causes it to migrate from the cytoplasm to membrane rafts (23). In control ScGT1 cells, activated cPLA2 was found predominantly in rafts, and more specifically cPLA2 co-localized to PrPSc-containing rafts (9). The addition of desialylated PrPC caused the dissociation of cPLA2 from rafts. The targeting of cPLA2 to membranes containing their substrates can regulate the formation of second messengers such as platelet-activating factor that facilitate PrPSc formation (21). We propose that the density of sialic acid attached to GPIs is critical to the stabilization and activation of cPLA2 in membrane rafts and that the binding of desialylated PrPC to PrPSc changed the composition of the underlying membrane so that it no longer captured and activated cPLA2. This reduced the activation of cPLA2 by existing PrPSc and hindered the conversion of PrPC to PrPSc. It is noteworthy that desialylated PrPC is surrounded by more gangliosides than PrPC, which is consistent with reports that gangliosides inhibit the activation of cPLA2 (4648).

Some of the PrPC extracted from hamster brains have GPIs that did not contain sialic acid (12). The chemical composition of the GPI anchor is cell type-specific 49), and the GPI anchor attached to PrPC derived from a glial cell line (N9 cells) does not contain sialic acid (13). More recently we found that some neuronal cell lines produce predominantly desialylated PrPC, suggesting that these cells may be resistant to prion infection, an observation that may explain the different sensitivities of neurons to prion infection.

In conclusion, we show that sialic acid attached to the GPI affects the properties of PrPC, altering the surrounding cell membrane, trafficking of PrPC, and PrPC-induced cell signaling. Critically the presence of desialylated PrPC reduced the activation of cPLA2 and PrPSc formation in prion-infected neuronal cells. We propose that sialic acid on the GPI anchor attached to PrPC affects the membrane targeting and cell signaling that is conducive to its conversion to PrPSc. Consequently, therapeutics that block the incorporation of sialic acid into GPI anchors could prove useful in the treatment of prion diseases.

Author Contributions

C. B. was responsible for conception and design, data collection and analysis, and manuscript writing and revision; W. N. was responsible for experimental design, and data collection and analysis; and A. W. was responsible for conception and design and manuscript writing. All authors read and approved the final manuscript.

Acknowledgment

We thank Dr. Mourad Tayebi for supplying mAbs ICSM18 and ICSM35.

*

This work was supported by a grant from the European Commission FP6 “Neuroprion” Network of Excellence. The authors declare that they have no conflicts of interest with the contents of this article.

2
The abbreviations used are:
GPI
glycosylphosphatidylinositol
cPLA2
cytoplasmic phospholipase A2
PLAP
phospholipase A2-activating peptide
DRM
detergent-resistant membrane
HPTLC
high performance thin layer chromatography.

References

  • 1.Pan K. M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R. J., and Cohen F. E. (1993) Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U.S.A. 90, 10962–10966 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Büeler H., Aguzzi A., Sailer A., Greiner R. A., Autenried P., Aguet M., and Weissmann C. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73, 1339–1347 [DOI] [PubMed] [Google Scholar]
  • 3.Taylor D. R., and Hooper N. M. (2006) The prion protein and lipid rafts. Mol. Membr. Biol. 23, 89–99 [DOI] [PubMed] [Google Scholar]
  • 4.Taraboulos A., Scott M., Semenov A., Avrahami D., Laszlo L., Prusiner S. B., and Avraham D. (1995) Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol. 129, 121–132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Stahl N., Borchelt D. R., Hsiao K., and Prusiner S. B. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51, 229–240 [DOI] [PubMed] [Google Scholar]
  • 6.Chatterjee S., and Mayor S. (2001) The GPI-anchor and protein sorting. Cell Mol. Life Sci. 58, 1969–1987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chesebro B., Trifilo M., Race R., Meade-White K., Teng C., LaCasse R., Raymond L., Favara C., Baron G., Priola S., Caughey B., Masliah E., and Oldstone M. (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435–1439 [DOI] [PubMed] [Google Scholar]
  • 8.McNally K. L., Ward A. E., and Priola S. A. (2009) Cells expressing anchorless prion protein are resistant to scrapie infection. J. Virol. 83, 4469–4475 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bate C., and Williams A. (2011) Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling and reduces prion formation. J. Biol. Chem. 286, 8752–8758 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Legler D. F., Doucey M. A., Schneider P., Chapatte L., Bender F. C., and Bron C. (2005) Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. FASEB J. 19, 73–75 [DOI] [PubMed] [Google Scholar]
  • 11.Liu T., Li R., Pan T., Liu D., Petersen R. B., Wong B. S., Gambetti P., and Sy M. S. (2002) Intercellular transfer of the cellular prion protein. J. Biol. Chem. 277, 47671–47678 [DOI] [PubMed] [Google Scholar]
  • 12.Stahl N., Baldwin M. A., Hecker R., Pan K. M., Burlingame A. L., and Prusiner S. B. (1992) Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry 31, 5043–5053 [DOI] [PubMed] [Google Scholar]
  • 13.Bate C., and Williams A. (2012) Neurodegeneration induced by the clustering of sialylated glycosylphosphatidylinositols of prion proteins. J. Biol. Chem. 287, 7935–7944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bate C., Tayebi M., and Williams A. (2010) The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication. Biochem. J. 428, 95–101 [DOI] [PubMed] [Google Scholar]
  • 15.Bate C. A., and Kwiatkowski D. (1994) A monoclonal antibody that recognizes phosphatidylinositol inhibits induction of tumor necrosis factor alpha by different strains of Plasmodium falciparum. Infect. Immun. 62, 5261–5266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Haraguchi T., Fisher S., Olofsson S., Endo T., Groth D., Tarentino A., Borchelt D. R., Teplow D., Hood L., and Burlingame A. (1989) Asparagine-linked glycosylation of the scrapie and cellular prion proteins. Arch. Biochem. Biophys. 274, 1–13 [DOI] [PubMed] [Google Scholar]
  • 17.Sunyach C., Jen A., Deng J., Fitzgerald K. T., Frobert Y., Grassi J., McCaffrey M. W., and Morris R. (2003) The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J. 22, 3591–3601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wilson B. S., Steinberg S. L., Liederman K., Pfeiffer J. R., Surviladze Z., Zhang J., Samelson L. E., Yang L. H., Kotula P. G., and Oliver J. M. (2004) Markers for detergent-resistant lipid rafts occupy distinct and dynamic domains in native membranes. Mol. Biol. Cell 15, 2580–2592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bate C., Tayebi M., Diomede L., Salmona M., and Williams A. (2009) Glimepiride reduces the expression of PrPC, prevents PrPSc formation, and protects against prion mediated neurotoxicity. PLoS One 4, e8221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Müller G., Dearey E. A., and Pünter J. (1993) The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. Biochem. J. 289, 509–521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bate C., Reid S., and Williams A. (2004) Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J. Biol. Chem. 279, 36405–36411 [DOI] [PubMed] [Google Scholar]
  • 22.Bate C., and Williams A. (2011) Amyloid-β-induced synapse damage is mediated via cross-linkage of the cellular prion protein. J. Biol. Chem. 286, 37955–37963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nalefski E. A., Sultzman L. A., Martin D. M., Kriz R. W., Towler P. S., Knopf J. L., and Clark J. D. (1994) Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca2+-dependent lipid-binding domain and a Ca2+-independent catalytic domain. J. Biol. Chem. 269, 18239–18249 [PubMed] [Google Scholar]
  • 24.Barboni E., Rivero B. P., George A. J., Martin S. R., Renoup D. V., Hounsell E. F., Barber P. C., and Morris R. J. (1995) The glycophosphatidylinositol anchor affects the conformation of Thy-1 protein. J. Cell Sci. 108, 487–497 [DOI] [PubMed] [Google Scholar]
  • 25.Nicholson T. B., and Stanners C. P. (2006) Specific inhibition of GPI-anchored protein function by homing and self-association of specific GPI anchors. J. Cell Biol. 175, 647–659 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Pike L. J. (2004) Lipid rafts: heterogeneity on the high seas. Biochem. J. 378, 281–292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Madore N., Smith K. L., Graham C. H., Jen A., Brady K., Hall S., and Morris R. (1999) Functionally different GPI proteins are organized in different domains on the neuronal surface. EMBO J. 18, 6917–6926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Puig B., Altmeppen H. C., Thurm D., Geissen M., Conrad C., Braulke T., and Glatzel M. (2011) N-Glycans and glycosylphosphatidylinositol-anchor act on polarized sorting of mouse PrP(C) in Madin-Darby canine kidney cells. PLoS One 6, e24624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Anderson R. G., and Jacobson K. (2002) A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296, 1821–1825 [DOI] [PubMed] [Google Scholar]
  • 30.Homans S. W., Ferguson M. A., Dwek R. A., Rademacher T. W., Anand R., and Williams A. F. (1988) Complete structure of the glycosyl phosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein. Nature 19, 269–272 [DOI] [PubMed] [Google Scholar]
  • 31.Brügger B., Graham C., Leibrecht I., Mombelli E., Jen A., Wieland F., and Morris R. (2004) The membrane domains occupied by glycosylphosphatidylinositol-anchored prion protein and Thy-1 differ in lipid composition. J. Biol. Chem. 279, 7530–7536 [DOI] [PubMed] [Google Scholar]
  • 32.Naslavsky N., Shmeeda H., Friedlander G., Yanai A., Futerman A. H., Barenholz Y., and Taraboulos A. (1999) Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J. Biol. Chem. 274, 20763–20771 [DOI] [PubMed] [Google Scholar]
  • 33.Cantù L., Del Favero E., Sonnino S., and Prinetti A. (2011) Gangliosides and the multiscale modulation of membrane structure. Chem. Phys. Lipids 164, 796–810 [DOI] [PubMed] [Google Scholar]
  • 34.Slotte J. P. (1999) Sphingomyelin-cholesterol interactions in biological and model membranes. Chem. Phys. Lipids 102, 13–27 [DOI] [PubMed] [Google Scholar]
  • 35.Ohmi Y., Ohkawa Y., Yamauchi Y., Tajima O., Furukawa K., and Furukawa K. (2012) Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem. Res. 37, 1185–1191 [DOI] [PubMed] [Google Scholar]
  • 36.Brown D. A., and London E. (2000) Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275, 17221–17224 [DOI] [PubMed] [Google Scholar]
  • 37.Simons M., Friedrichson T., Schulz J. B., Pitto M., Masserini M., and Kurzchalia T. V. (1999) Exogenous administration of gangliosides displaces GPI-anchored proteins from lipid microdomains in living cells. Mol. Biol. Cell 10, 3187–3196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nagafuku M., Kabayama K., Oka D., Kato A., Tani-ichi S., Shimada Y., Ohno-Iwashita Y., Yamasaki S., Saito T., Iwabuchi K., Hamaoka T., Inokuchi J., and Kosugi A. (2003) Reduction of glycosphingolipid levels in lipid rafts affects the expression state and function of glycosylphosphatidylinositol-anchored proteins but does not impair signal transduction via the T cell receptor. J. Biol. Chem. 278, 51920–51927 [DOI] [PubMed] [Google Scholar]
  • 39.Galvan C., Camoletto P. G., Dotti C. G., Aguzzi A., and Ledesma M. D. (2005) Proper axonal distribution of PrPC depends on cholesterol-sphingomyelin-enriched membrane domains and is developmentally regulated in hippocampal neurons. Mol. Cell Neurosci. 30, 304–315 [DOI] [PubMed] [Google Scholar]
  • 40.Taylor D. R., Watt N. T., Perera W. S., and Hooper N. M. (2005) Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J. Cell Sci. 118, 5141–5153 [DOI] [PubMed] [Google Scholar]
  • 41.Schiff E., Campana V., Tivodar S., Lebreton S., Gousset K., and Zurzolo C. (2008) Coexpression of wild-type and mutant prion proteins alters their cellular localization and partitioning into detergent-resistant membranes. Traffic 9, 1101–1115 [DOI] [PubMed] [Google Scholar]
  • 42.Montixi C., Langlet C., Bernard A.-M., Thimonier J., Dubois C., Wurbel M.-A., Chauvin J.-P., Pierres M., and He H.-T. (1998) Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J. 17, 5334–5348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Eisenberg S., Shvartsman D. E., Ehrlich M., and Henis Y. I. (2006) Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-Ras diffusion and signaling. Mol. Cell Biol. 26, 7190–7200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Gri G., Molon B., Manes S., Pozzan T., and Viola A. (2004) The inner side of T cell lipid rafts. Immunol. Lett. 94, 247–252 [DOI] [PubMed] [Google Scholar]
  • 45.Field K. A., Holowka D., and Baird B. (1995) Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling. Proc. Natl. Acad. Sci. U.S.A. 92, 9201–9205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bianco I. D., Fidelio G. D., and Maggio B. (1989) Modulation of phospholipase A2 activity by neutral and anionic glycosphingolipids in monolayers. Biochem. J. 258, 95–99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Maggio B., Bianco I. D., Montich G. G., Fidelio G. D., and Yu R. K. (1994) Regulation by gangliosides and sulfatides of phospholipase A2 activity against dipalmitoyl- and dilauroylphosphatidylcholine in small unilamellar bilayer vesicles and mixed monolayers. Biochim. Biophys. Acta 1190, 137–148 [DOI] [PubMed] [Google Scholar]
  • 48.Yang H. C., Farooqui A. A., and Horrocks L. A. (1994) Effects of glycosaminoglycans and glycosphingolipids on cytosolic phospholipases A2 from bovine brain. Biochem. J. 299, 91–95 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.McConville M. J., and Ferguson M. A. (1993) The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem. J. 294, 305–324 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES